Your browser doesn't support javascript.
loading
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients.
Radtke, Andrea J; Postovalova, Ekaterina; Varlamova, Arina; Bagaev, Alexander; Sorokina, Maria; Kudryashova, Olga; Meerson, Mark; Polyakova, Margarita; Galkin, Ilia; Svekolkin, Viktor; Isaev, Sergey; Wiebe, Daniil; Sharun, Anna; Sarachakov, Alexander; Perelman, Grigory; Lozinsky, Yaroslav; Yaniv, Ziv; Lowekamp, Bradley C; Speranza, Emily; Yao, Li; Pittaluga, Stefania; Shaffer, Arthur L; Jonigk, Danny; Phelan, James D; Davies-Hill, Theresa; Huang, Da Wei; Ovcharov, Pavel; Nomie, Krystle; Nuzhdina, Ekaterina; Kotlov, Nikita; Ataullakhanov, Ravshan; Fowler, Nathan; Kelly, Michael; Muppidi, Jagan; Davis, Jeremy L; Hernandez, Jonathan M; Wilson, Wyndham H; Jaffe, Elaine S; Staudt, Louis M; Roschewski, Mark; Germain, Ronald N.
Afiliação
  • Radtke AJ; Lymphocyte Biology Section and Center for Advanced Tissue Imaging, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD 20892, USA. Electronic address: andrea.radtke@nih.gov.
  • Postovalova E; BostonGene, Waltham, MA 02453, USA.
  • Varlamova A; BostonGene, Waltham, MA 02453, USA.
  • Bagaev A; BostonGene, Waltham, MA 02453, USA.
  • Sorokina M; BostonGene, Waltham, MA 02453, USA.
  • Kudryashova O; BostonGene, Waltham, MA 02453, USA.
  • Meerson M; BostonGene, Waltham, MA 02453, USA.
  • Polyakova M; BostonGene, Waltham, MA 02453, USA.
  • Galkin I; BostonGene, Waltham, MA 02453, USA.
  • Svekolkin V; BostonGene, Waltham, MA 02453, USA.
  • Isaev S; BostonGene, Waltham, MA 02453, USA.
  • Wiebe D; BostonGene, Waltham, MA 02453, USA.
  • Sharun A; BostonGene, Waltham, MA 02453, USA.
  • Sarachakov A; BostonGene, Waltham, MA 02453, USA.
  • Perelman G; BostonGene, Waltham, MA 02453, USA.
  • Lozinsky Y; BostonGene, Waltham, MA 02453, USA.
  • Yaniv Z; Bioinformatics and Computational Bioscience Branch, NIAID, NIH, Bethesda, MD 20892, USA.
  • Lowekamp BC; Bioinformatics and Computational Bioscience Branch, NIAID, NIH, Bethesda, MD 20892, USA.
  • Speranza E; Lymphocyte Biology Section and Center for Advanced Tissue Imaging, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD 20892, USA; Florida Research and Innovation Center, Cleveland Clinic Lerner Research Institute, Port Saint Lucie, FL 34987, USA.
  • Yao L; Li Yao Visuals, Rockville, MD 20855, USA.
  • Pittaluga S; Laboratory of Pathology, NCI, NIH, Bethesda, MD 20892, USA.
  • Shaffer AL; Lymphoid Malignancies Branch, NCI, NIH, Bethesda, MD 20892, USA; Tumor Targeted Delivery, Heme Malignancy Target Discovery Group, AstraZeneca, Gaithersburg, MD 20878, USA.
  • Jonigk D; Institute of Pathology, Aachen Medical University, RWTH Aachen, 52074 Aachen, Germany; German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), 30625 Hannover, Germany.
  • Phelan JD; Lymphoid Malignancies Branch, NCI, NIH, Bethesda, MD 20892, USA.
  • Davies-Hill T; Laboratory of Pathology, NCI, NIH, Bethesda, MD 20892, USA.
  • Huang DW; Lymphoid Malignancies Branch, NCI, NIH, Bethesda, MD 20892, USA.
  • Ovcharov P; BostonGene, Waltham, MA 02453, USA.
  • Nomie K; BostonGene, Waltham, MA 02453, USA.
  • Nuzhdina E; BostonGene, Waltham, MA 02453, USA.
  • Kotlov N; BostonGene, Waltham, MA 02453, USA.
  • Ataullakhanov R; BostonGene, Waltham, MA 02453, USA.
  • Fowler N; BostonGene, Waltham, MA 02453, USA.
  • Kelly M; CCR Single Analysis Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Bethesda, MD 20892, USA.
  • Muppidi J; Lymphoid Malignancies Branch, NCI, NIH, Bethesda, MD 20892, USA.
  • Davis JL; Surgical Oncology Program, Metastasis Biology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Hernandez JM; Surgical Oncology Program, Metastasis Biology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Wilson WH; Lymphoid Malignancies Branch, NCI, NIH, Bethesda, MD 20892, USA.
  • Jaffe ES; Laboratory of Pathology, NCI, NIH, Bethesda, MD 20892, USA.
  • Staudt LM; Lymphoid Malignancies Branch, NCI, NIH, Bethesda, MD 20892, USA.
  • Roschewski M; Lymphoid Malignancies Branch, NCI, NIH, Bethesda, MD 20892, USA.
  • Germain RN; Lymphocyte Biology Section and Center for Advanced Tissue Imaging, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD 20892, USA.
Cancer Cell ; 42(3): 444-463.e10, 2024 Mar 11.
Article em En | MEDLINE | ID: mdl-38428410
ABSTRACT
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Dynamic interactions between tumor B cells and the tumor microenvironment (TME) are hypothesized to contribute to the broad spectrum of clinical behaviors observed among FL patients. Despite the urgent need, existing clinical tools do not reliably predict disease behavior. Using a multi-modal strategy, we examined cell-intrinsic and -extrinsic factors governing progression and therapeutic outcomes in FL patients enrolled onto a prospective clinical trial. By leveraging the strengths of each platform, we identify several tumor-specific features and microenvironmental patterns enriched in individuals who experience early relapse, the most high-risk FL patients. These features include stromal desmoplasia and changes to the follicular growth pattern present 20 months before first progression and first relapse.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Folicular Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Folicular Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article